Ophthalmic surgery, lasers & imaging retina · 2025
Outcomes of Complex PVR Retinal Detachment Repair With and Without Intravitreal Methotrexate at a Single Tertiary Care Center.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ploumi Ioanna, Garcia Mauricio D, Zhu Ying, Nodecker Kayla N, Shah Shivesh H, Xu Wenxuan, Miller John B
Аннотация
BACKGROUND AND OBJECTIVE: Proliferative vitreoretinopathy (PVR) remains the leading cause of failed retinal detachment (RD) repair. This study evaluated anatomic and visual outcomes in complex Grade C PVR RDs by advanced vitreoretinal techniques with or without adjunctive intravitreal met hotrexate (MTX).
PATIENTS AND METHODS: This retrospective consecutive case series included eyes undergoing surgical repair at a single tertiary care center. Outcomes were compared in complex RDs repaired by advanced surgical maneuvers with or without adjunctive MTX. The primary endpoint was single-surgery retinal attachment, assessed at 3 to 5 months, 1 year, and final follow-up. Secondary endpoints included visual acuity (VA), outcomes after silicone oil removal, and corneal epitheliopathy.
RESULTS: There were no significant difference in single-surgery retinal reattachment rates (P = 1.00) or VA (P > 0.05) at any timepoint. The number of MTX injections was not associated with improved odds of single-surgery reattachment (OR = 1.02, P = 0.73). Mild corneal epitheliopathy was observed in 28.8% of MTX-treated eyes.
CONCLUSION: Adding intravitreal MTX to advanced vitreoretinal repair techniques did not show significant improvement in the outcomes of complex Grade C PVR RDs. Additional refinement of treatment criteria is likely needed to identify which patients may benefit the most from this additional treatment.
PATIENTS AND METHODS: This retrospective consecutive case series included eyes undergoing surgical repair at a single tertiary care center. Outcomes were compared in complex RDs repaired by advanced surgical maneuvers with or without adjunctive MTX. The primary endpoint was single-surgery retinal attachment, assessed at 3 to 5 months, 1 year, and final follow-up. Secondary endpoints included visual acuity (VA), outcomes after silicone oil removal, and corneal epitheliopathy.
RESULTS: There were no significant difference in single-surgery retinal reattachment rates (P = 1.00) or VA (P > 0.05) at any timepoint. The number of MTX injections was not associated with improved odds of single-surgery reattachment (OR = 1.02, P = 0.73). Mild corneal epitheliopathy was observed in 28.8% of MTX-treated eyes.
CONCLUSION: Adding intravitreal MTX to advanced vitreoretinal repair techniques did not show significant improvement in the outcomes of complex Grade C PVR RDs. Additional refinement of treatment criteria is likely needed to identify which patients may benefit the most from this additional treatment.